AbbVie expects the acquisition to generate at least $2 billion in pre-tax synergies and cost reductions within three years.
Shares of Allergan surged more than 30% in early trading on Tuesday after AbbVie agreed to acquire the drugmaker for $63 billion. AbbVie's bid of $188 a share in cash and stock represents a 45% premium from Allergan's closing price on Monday. The acquisition will give AbbVie access to Allergan's portfolio of profitable beauty drugs, including Botox. Watch Allergan trade live.
Shares of Allergan surged more than 30% in early trading on Tuesday after AbbVie agreed to acquire the drugmaker for $63 billion. AbbVie's bid of $188 a share in cash and stock represents a 45% premium from Allergan's closing price on Monday. The acquisition will give AbbVie access to Allergan's portfolio of profitable beauty drugs, including Botox. Watch Allergan trade live.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
AbbVie confirms deal to buy Allergan for 45% premium, valuing Allergan at $61.7 billionAbbVie Inc. confirmed Tuesday a deal to buy pharmaceutical company Allergan PLC , in a deal with equity value of $63 billion. Allergan's stock soared 30% in...
Consulte Mais informação »
AbbVie Strikes Deal to Buy Allergan for About $63 BillionAbbVie has reached a deal to buy Allergan for about $63 billion, as two big drugmakers bet a combination will deliver new sources of growth they have struggled to find on their own.
Consulte Mais informação »
Abbvie is buying Allergan in a $63 billion pharma mega-dealThe biopharmaceuticals giant and drugmaker are combining to create a leader across immunology, neuroscience, eye care and other medical fields.
Consulte Mais informação »
AbbVie Nears Deal to Buy Allergan for More Than $60 BillionAbbVie is nearing a deal to buy Allergan for more than $60 billion, as the two big drug makers bet a combination will deliver new sources of growth they have struggled to find on their own.
Consulte Mais informação »
Abbvie is buying Allergan in a $63 billion pharma mega-dealThe biopharmaceuticals giant and drugmaker are combining to create a leader across immunology, neuroscience, eye care and other medical fields.
Consulte Mais informação »